Clinical Trials Logo
  1. Home
  2. Cardiogenic Shock
  3. NCT05730907
  4. Details
NCT05730907 Clinical Trial

Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Cardiogenic Shock Clinical Trial

— ECPR  

Official title:
Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05730907
Other study ID # MRC-01-21-282
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 20, 2023
Est. completion date April 30, 2023

Study information
Verified date November 2022
Source Hamad Medical Corporation
Contact Rasha Kaddoura, Msc
Phone 44395897
Email rasha.kaddoura@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Recruitment information / eligibility
Status Recruiting
Enrollment 100
Est. completion date April 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility IInclusion criteria: - Hospitalized patients = 18 years of age at the time of E-CPR use - Patients suffered cardiac arrest (IHCA or OHCA) - Patients received VA-ECMO for E-CPR - Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol) Exclusion criteria: - Patients with incomplete key data - Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Levosimendan
examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR

Locations
Country Name City State
Qatar Hamad medical corporation Doha DA

Sponsors (1)
Lead Sponsor Collaborator
Hamad Medical Corporation

Country where clinical trial is conducted

Qatar, 

Outcome
Type Measure Description Time frame Safety issue
Primary Survival to hospital discharge Survival to hospital discharge with good neurological outcomes 6 months
Secondary Survival to decannulation Survival to decannulation with good neurological outcomes 6 months
Secondary long term survival long term survival 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT02301819 - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05728359 - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A